|1.||Cao, Chuanwang: 1 article (05/2014)|
|2.||Fang, Kui: 1 article (05/2014)|
|3.||Pan, Yiou: 1 article (05/2014)|
|4.||Shang, Qingli: 1 article (05/2014)|
|5.||Brennan, James Andrew: 1 article (05/2014)|
|6.||Xi, Jinghui: 1 article (05/2014)|
|7.||Wong, Andrew: 1 article (05/2014)|
|8.||Szilasi, Mária: 1 article (01/2011)|
|9.||Bognár, Gabriella: 1 article (01/2011)|
|10.||Forgács, Zsolt: 1 article (01/2011)|
06/01/1985 - "For the malaoxon study, the only difference between the original and subsequent interpretations was for C-cell neoplasms of the thyroid gland, in that the NTP concluded there was equivocal evidence of carcinogenicity for male and female F344 rats."
06/01/1985 - "Benign and malignant neoplasms at all sites, and in the endocrine organs, were increased in Fischer-344 male and female rats ingesting malaoxon. "
03/13/1998 - "Therefore, this study examined concentration-related OP-induced inhibition of CbxE in human SH-SY5Y and mouse NB41A3 neuroblastoma cells with 11 active esterase inhibitors: paraoxon, malaoxon, chlorpyrifos-oxon, tolyl saligenin phosphate (TSP), phenyl saligenin phosphate (PSP), diisopropyl phosphorofluoridate (DFP), mipafox, dichlorvos, trichlorfon, dibutyryl dichlorovinyl phosphate (DBVP), and dioctyl dichlorovinyl phosphate (DOVP). "
|3.||Chromosome Aberrations (Chromosome Abnormalities)
01/01/1992 - "Malaoxon (8.2 mg/kg) did not produce convulsions in non-pregnant female rats. "
01/01/1992 - "A dose of malaoxon OP, which produced convulsions in about 60% of the exposed rats in different rat groups, was 39.2 for male, and 8.2 mg/kg for pregnant female rats, respectively. "
02/01/1989 - "In nonconvulsing rats, the Ins1P-levels reached their maximum 1-4 hr after the administration of malaoxon, whereas in convulsing rats the levels increased for 72 hr. The results suggest that PI-signalling is associated with convulsions produced by malaoxon."
02/01/1989 - "The potential of a single dose of malaoxon (26.2 or 39.2 mg/kg i.p.) to produce convulsions and to increase cerebral levels of inositol-1-phosphate (Ins1P), an intermediate in phosphoinositide (PI) cycle, was followed for 1, 4, or 72 hr. The lower dose of malaoxon did not produce convulsions whereas the higher dose induced convulsions in 60% of the exposed rats. "
06/15/1990 - "Convulsions, neuronal morphology, brain phosphoinositide (PI) signaling, and calcium levels were studied in rats 1, 4, and 72 hr after malaoxon (MO; 26.2 or 39.2 mg/kg ip) subsequent to pretreatment with saline or LiCl (10 meq/kg ip). "
01/01/2002 - "In the case of malaoxon earwig and green lacewing AChEs were much more sensitive than AChE of the ladybird beetle. "
05/01/2014 - "Furthermore, in both the mutant and susceptible AChEs, Ace2 was significantly less sensitive to eserine, omethoate, and malaoxon than Ace1. "
05/01/2014 - "In vitro functional expression of AChEs reveals that the resistant Ace1 (Ace1R) and Ace2 (Ace2R) were significantly less inhibited by eserine, omethoate, and malaoxon than the susceptible Ace1 (Ace1S) and Ace2 (Ace2S). "
08/27/2010 - "Biochemical characterization of the recombinant proteins supports classification of rBmAChE1, rBmAChE2, and rBmAChE3 as AChEs (E.C.184.108.40.206), as evidenced by (i) substrate preference for acetylthiocholine, (ii) inhibition by eserine, BW284c51, and the organophosphates (OPs) malaoxon and paraoxon, (iii) insensitivity to iso-OMPA, and (iv) rapid hydrolysis of acetyl-beta-methyl-thiocholine. "
|6.||phenylsaligenin cyclic phosphate (PSCP)
|7.||salicyl alcohol (saligenin)
|8.||O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate